| Brand Name: | Sichuan Kelun Pharmaceutical Co., Ltd. |
| Model Number: | Lenvatinib KL-20213946 |
| MOQ: | Negotiable |
| Price: | Please contact a specialist WhatsApp:55342706 |
| Delivery Time: | Negotiable |
| Payment Terms: | Western Union,MoneyGram,T/T |
Generic Name: Lenvatinib Mesilate
Brand Name: Lundaxin
Specification: 4mg x 30 Capsules
Lenvatinib Mesilate
1. Radioactive iodine-refractory differentiated thyroid cancer. 2. First-line unresectable HCC. 3. Advanced RCC with everolimus.
Multi-targeted TKI inhibiting VEGFR1-3, FGFR1-4, PDGFRa, c-KIT, RET. Dual anti-angiogenic and direct antitumor activity.
DTC: 24mg daily. HCC: 8mg (<60kg) or 12mg (>=60kg) daily. RCC: 18mg with everolimus. Dose modify in 4mg increments.
Hypertension (73%), fatigue, diarrhea (67%), decreased appetite, hand-foot syndrome, proteinuria. Cardiac dysfunction, hepatotoxicity, hemorrhage, RPLS.
Store below 30C. Keep out of reach of children.
24 months
Approval: H20213946